RecruitingPhase 1NCT06012734

LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients

Phase Ib Study With the Combination of LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients - The CoLBAt Trial

Sponsor

The Netherlands Cancer Institute

Enrollment

37 participants

Start Date

Jun 18, 2024

Study Type

INTERVENTIONAL

Conditions

Metastatic Microsatellite-stable Colorectal Cancer

Summary

This Phase Ib trial studies the side effects and best dose of LB-100 when given with atezolizumab for the treatment of patients with metastatic microsatellite stable colorectal cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of the tumor to grow and spread. LB-100 has been shown to make anticancer drugs work better at killing cancer. LB-100 blocks a protein on the surface of cells called PP2A. Blocking this protein increases the stress signals for the tumor cells that express PP2A. Giving atezolizumab in combination with LB-100 may work better to treat metastatic colorectal cancer patients as the cancer cells that experience increased stress signals are more susceptible for the immunotherapy.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing a combination of LB-100 (a drug that helps the immune system recognize cancer cells) and atezolizumab (an immunotherapy drug) in people with metastatic colorectal cancer that is microsatellite stable (MSS) — a type that typically doesn't respond well to immunotherapy. **You may be eligible if...** - You are 18 or older - You have confirmed metastatic colorectal cancer that is MSS (microsatellite stable) - Your cancer has progressed on standard treatments - You have at least one measurable tumor on imaging - You are in good health (ECOG 0–1) with a life expectancy of at least 3 months - Your blood counts, liver, kidney, and heart function are within acceptable ranges - HIV and hepatitis tests are negative (or HIV is well controlled) **You may NOT be eligible if...** - Your cancer is not MSS - You are unwilling to provide tumor biopsy samples - You have uncontrolled infections or serious autoimmune disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLB-100

IV on day 1 and day 3

DRUGAtezolizumab

IV on day 1

Locations(1)

Antoni van Leeuwenhoek

Amsterdam, North Holland, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06012734

Related Trials

Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC

NCT0576850312 locations